he Japanese government is probing a scandal over allegations that Bayer may have improperly instructed a former sales rep to gather patient data that was used to prepare medical journal papers for promoting its Xarelto blood thinner, according to Pharma Japan.

The Ministry of Health, Labor, and Welfare is reportedly examining whether the company continued to use the papers — which might actually constitute promotional materials — after these were withdrawn in 2016. If Bayer had done so, the drug maker might have violated a law regarding false and misleading advertising, the web site explained.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.